Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Cancer

ASCO 2015: Pre-conference review

This article was originally published in Scrip

In this roundtable The Pink Sheet’s Mary Jo Laffler talks to experts from Datamonitor Healthcare, Citeline and BioMedTracker about their top picks from this year's ASCO abstracts, as well as other news to watch out for at the 2015 conference at the end of this month.

They discuss highlights in the area of immune-oncology, specifically new combination drug candidates; game-changing data expected for myeloma therapies; how companies are looking at new approaches for old targets in oncology; and more.

ASCO 2015 Pre-Conference Review from Datamonitor Healthcare on Vimeo.

Related stories:

Big pharma's immunotherapy game at ASCO

Good, Bad, Ugly: the ASCO abstracts are out

For more coverage on ASCO 2015:

www.scripintelligence.com

www.biomedtracker.com

www.datamonitorhealthcare.com

www.citeline.com

The Pink Sheet

Table

View full table

Topics

Tags:
Cancer
Latest Headlines

Finance Watch: Investors Support Strategic Shifts At Cullinan, Cidara

Humira Market Erosion Is Continuing As Expected, AbbVie Says

Pfizer Matches Beqvez Price To Hemgenix In Hemophilia B, Plans Warranty Program

Analysis: Novo And Lilly Make Their Money Work

See All
UsernamePublicRestriction

Register

SC028797

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By